Researchers are reporting promising results for people with mesothelioma who can have surgery. One researcher tested immunotherapy before and after surgery while the other researcher studied a blood test that helps doctors detect mesothelioma earlier than scans. Doctors at several cancer centers, including Johns Hopkins, ran an early clinical trial[…]
Keytruda
Immunotherapy Might Not Be a Good Option for Mesothelioma
Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure that creates challenges for patients and caregivers. Immune checkpoint inhibitors have brought hope to patients, but new data from Australia is raising questions about their safety and effectiveness. In order to make informed decisions, patients must understand all[…]
Keytruda and Chemotherapy Improve Survival in Mesothelioma Patients
The U.S Food and Drug Administration has accepted a priority review for a new Supplemental Biologics License Application. This could be a new era in the management of pleural mesothelioma, leading to a better future for those diagnosed with the cancer. The review is looking for approval of Keytruda used[…]
Galinpepimut-S Alongside Opdivo Improves Survival in Mesothelioma Patients
Sellas Life Sciences recently reported results from its Phase I clinical trial showing that survival was improved in pleural mesothelioma patients due to its treatment. The trial looked at the treatment called galinpepimut-S (GPS), an immunotherapy vaccine. There were 10 patients in the study with relapsed or refractory mesothelioma. Nine[…]
Pembrolizumab and Chemotherapy Improve Survival in Patients
Pleural mesothelioma, a cancer mainly caused by asbestos, is a hard cancer to treat. Diagnosis usually occurs when it is in a late stage, leading to limited treatment options. New clinical trials are always being performed to try to find a new treatment approach that could possibly extend the lives[…]
Chemoimmunotherapy Benefits Pleural Mesothelioma Patients
Results from a phase 3 clinical trial were recently published in the Journal of Clinical Oncology showing that a combination of chemotherapy and immunotherapy for mesothelioma improves patients’ survival more than chemotherapy alone. Researchers combined Keytruda, or pembrolizumab, with platinum and pemetrexed chemotherapy. The overall response rate for patients receiving[…]
Keytruda Helps Improve Survival for Mesothelioma When Used Alongside Chemotherapy
Keytruda is showing promising results for the treatment of pleural mesothelioma. Researchers found that the combination of Keytruda (pembrolizumab) and chemotherapy lead to a better survival in patients versus chemotherapy alone. Mesothelioma is a hard-to-treat cancer with no cure. It can be found in the linings of the lungs, abdomen,[…]
Keytruda as a Second Line Treatment for Mesothelioma
A new second line treatment has been developed for pleural mesothelioma. The treatment was created at the Netherlands Cancer Institute in Amsterdam. Research was done as a single-arm, open-label clinical trial combining pembrolizumab (Keytruda) and lenvatinib. The results were presented at the IASCL 2022 World Conference on Lung Cancer in[…]
OT-101 Useful for COVID-19 and Cancers Like Mesothelioma
Researchers are looking at a new treatment for mesothelioma. It is a multimodal treatment (multiple treatments combined) consisting of the immunotherapy drug Keytruda and a new drug called OT-101. OT-101 is an antisense drug, which is a drug that blocks molecules that make certain proteins. The drug is also effective[…]
Durvalumab and Chemotherapy Extends Mesothelioma Patients’ Lives
Studies are showing that the immunotherapy drug durvalumab can make chemotherapy more effective for treating mesothelioma. Durvalumab is an immunotherapy drug called an immune checkpoint inhibitor. It blocks the protein PD-1, which is used by mesothelioma cells to protect themselves. Researchers believed that if the protein was blocked, mesothelioma cells[…]
